BIO recently released the largest study of clinical drug development success rates to date, which reported that the average overall likelihood of approval (LOA) by FDA from Phase 1 for all developmental candidates was only 9.6 percent – and of the 14 major disease areas, oncology had the lowest LOA at 5.1 percent. In addition…